SEPAX®2 is an FDA approved fully automated cell separation system that is widely recognized as the industry standard in cord blood banking globally. Almost half of the worldwide processing procedures for cord blood inventory were processed with SEPAX®2. The system is one of the most efficient and consistent platforms that can recover as much as 99.46%* of cells from a cord blood unit and provides exceptional post-thaw cell viability count. This is a critical factor in ensuring a successful stem cell transplant. One other unique feature of SEPAX®2 is it processes one cord blood unit at a time in a closed system format, limiting the risk of cross-contamination and sample mix up.
“As a leading healthcare company in Asia, we are committed to delivering the highest of quality standards in our service and product offerings. We firmly believe that our upgrade to SEPAX®2 will help provide our clients with world-class quality cord blood stem cells in the event when a transplant becomes necessary”, said Mr Meghnath Roy Chowdhury, Managing Director, CordLife.
Cordlife has also extended its cord blood and umbilical cord storage tenure to 25 years instead of the usual industry practice of 18 years. This move further demonstrates the company’s commitment to be around in India for the long haul for the benefit of their clients.
Cordlife and its parent company Cordlife Group Limited, have been in the forefront of the industry in Asia for more than 12 years. Cord blood stem cells, obtained from the umbilical cord immediately following birth, are currently used to treat diseases such as leukemia, lymphoma and thalassemia major. Successful transplants for these indications occur regularly at hospitals both domestically and internationally. To enhance the effectiveness of a cord blood transplant and to avail more medical options for families, Cordlife also offers umbilical cord banking service. Using its unique patented technology, CellOptima®, Cordlife is the only Company in India that can extract Epithelial stem cells and Mesenchymal stem cells from the umbilical cord.
*Based on actual internal processing data.
About CordLife Group Limited (Bloomberg Stock Code: CLGL)
Homegrown in Singapore and incorporated in 2001, Cordlife Group Limited (“CGL” or “the Group”) is a multi-product healthcare company catering to the mother and child segment and a leading cord blood and tissue banking services provider. Listed on the Mainboard of the Singapore Exchange and amongst the first private cord blood banks in Asia, CGL has established a dominant market leader position in Singapore. Apart from its AABB accredited (formerly known as the American Association of Blood Banks) flagship facility in Singapore, the Group also operates a wide network of private cord blood and tissue processing facilities in Hong Kong, India, Indonesia and the Philippines. CGL collects, processes, tests and cryopreserves stem cells from the cord blood and umbilical cord of a child at birth, allowing customers to preserve their child’s precious lifesaving resource for treatment later in his or her life if their child so requires. The Group also has a 10% direct stake in China Cord Blood Corporate – a top operator in China holding majority shares in Beijing, Guangdong and Zhejiang Cord Blood banks, as well as an approximately 20% share in Shandong Cord Blood Bank. For more information on the CordLife group of companies, please visit www.cordlife.com.
About CordLife Sciences India Pvt. Ltd
Cordlife India is AABB accredited and the most advanced umbilical cord and cord blood processing, testing and cryopreservation facility in the country, with a storage capacity of 150,000 cord blood units scalable by another few lakh units. The state-of-the-art laboratory is equipped with the latest and the most modern equipment in a clean-room infrastructure to ensure that stem cells are processed under the most sterile conditions. Their natural calamity proof building is also built with continuous power backup and round-the-clock surveillance system. Cordlife India has successfully released a stem cell unit for the first ever mixed stem cell transplant in India. The Company operates more than 50 centers in India, making it one of the largest stem cell banking companies locally. Visit www.cordlifeindia.com for more information.
